- Home
- DXLG vs NSRX Comparison
DXLG vs NSRX Comparison
Compare DXLG & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | NSRX |
|---|---|---|
| Founded | 1976 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 32.2M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXLG | NSRX |
|---|---|---|
| Price | $0.73 | $2.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.50 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 93.1K | 79.9K |
| Earning Date | 05-28-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $435,017,000.00 | N/A |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.09 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $1.98 |
| 52 Week High | $1.69 | $9.99 |
Technical Indicators
Market Signals| Indicator | DXLG | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 50.24 |
| Support Level | $0.48 | $2.04 |
| Resistance Level | $0.82 | $3.48 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 58.35 | 36.63 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.